{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:01:45Z","timestamp":1792620105633,"version":"4.5.0"},"reference-count":42,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2017,12,4]]},"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The introduction of biological disease-modifying antirheumatic drugs (bDMARDs) has improved the treatment of inflammatory rheumatic diseases dramatically. However, bDMARD treatment failure occurs in 30%\u201340% of patients due to lack of effect or adverse events, and the tools to predict treatment outcomes in individual patients are currently limited. The objective of the present study is to identify diagnostic, prognostic and predictive biomarkers, which can be used to (1) diagnose inflammatory rheumatic diseases early in the disease course with high sensitivity and specificity, (2) improve prognostication or (3) predict and monitor treatment effectiveness and tolerability for the individual patient.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>The present study is an observational and translational open cohort study with prospective collection of clinical data and biological materials (primarily blood) in patients with inflammatory rheumatic diseases treated in routine care. Patients contribute with one cross-sectional blood sample and\/or are enrolled for longitudinal follow-up on initiation of a new DMARD (blood sampling after 0, 3, 6, 12, 24, 36, 48, 60 months of treatment). Other biological materials will be collected when accessible and relevant. Demographics, disease characteristics, comorbidities and lifestyle factors are registered at inclusion; DMARD treatment and outcomes are collected repeatedly during follow-up. Currently (July 2017), &gt;5000 samples from approximately 3000 patients have been collected. Data will be analysed using appropriate statistical analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The protocol is approved by the Danish Ethics Committee and the Danish Data Protection Agency. Participants give written and oral informed consent. Biomarkers will be evaluated and published according to the Reporting Recommendations for Tumour Marker (REMARK) prognostic studies, Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) and the Standards for Reporting of Diagnostic Accuracy (STARD) guidelines. Results will be published in peer-reviewed scientific journals and presented at international conferences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>NCT03214263.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2017-019325","type":"journal-article","created":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T10:13:56Z","timestamp":1517480036000},"page":"e019325","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":25,"title":["Identification of new biomarkers to promote personalised treatment of patients with inflammatory rheumatic disease: protocol for an open cohort study"],"prefix":"10.1136","volume":"8","author":[{"given":"Tina Marie","family":"Kringelbach","sequence":"first","affiliation":[{"name":"The Danish Rheumatologic Biobank, Capital Region, Denmark"},{"name":"Bio- and Genome Bank Denmark, The Molecular Unit, Department of Pathology, Copenhagen University Hospital Herlev, Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bente","family":"Glintborg","sequence":"additional","affiliation":[{"name":"The Danish Rheumatologic Biobank, Capital Region, Denmark"},{"name":"Copenhagen Centre for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark"},{"name":"The Danish DANBIO Registry, Rigshospitalet, Glostrup, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estrid V","family":"Hogdall","sequence":"additional","affiliation":[{"name":"The Danish Rheumatologic Biobank, Capital Region, Denmark"},{"name":"Bio- and Genome Bank Denmark, The Molecular Unit, Department of Pathology, Copenhagen University Hospital Herlev, Herlev, Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia Sidenius","family":"Johansen","sequence":"additional","affiliation":[{"name":"The Danish Rheumatologic Biobank, Capital Region, Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"},{"name":"Department of Medicine, Copenhagen University Hospital Herlev, Herlev, Denmark"},{"name":"Department of Oncology, Copenhagen University Hospital Herlev, Herlev, Denamrk"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merete Lund","family":"Hetland","sequence":"additional","affiliation":[{"name":"The Danish Rheumatologic Biobank, Capital Region, Denmark"},{"name":"Copenhagen Centre for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark"},{"name":"The Danish DANBIO Registry, Rigshospitalet, Glostrup, Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,2,1]]},"reference":[{"key":"2025121220300172000_8.2.e019325.1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204080"},{"key":"2025121220300172000_8.2.e019325.2","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/art.40091","article-title":"Brief Report: rheumatoid arthritis as the underlying cause of death in thirty-one countries, 1987-2011: trend analysis of World Health Organization mortality database","volume":"69","author":"Kiadaliri","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025121220300172000_8.2.e019325.3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210715"},{"key":"2025121220300172000_8.2.e019325.4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207524"},{"key":"2025121220300172000_8.2.e019325.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208337"},{"key":"2025121220300172000_8.2.e019325.6","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3111\/13696998.2015.1099538","article-title":"Real-world evaluation of TNF-inhibitor utilization in rheumatoid arthritis","volume":"19","author":"Harnett","year":"2016","journal-title":"J Med Econ"},{"key":"2025121220300172000_8.2.e019325.7","doi-asserted-by":"publisher","DOI":"10.1002\/art.27227"},{"key":"2025121220300172000_8.2.e019325.8","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.135376"},{"key":"2025121220300172000_8.2.e019325.9","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2001.113989"},{"key":"2025121220300172000_8.2.e019325.10","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0b013e32833ed177"},{"key":"2025121220300172000_8.2.e019325.11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h5079"},{"key":"2025121220300172000_8.2.e019325.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2015.07.005"},{"key":"2025121220300172000_8.2.e019325.13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001216","article-title":"Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration","volume":"9","author":"Altman","year":"2012","journal-title":"PLoS Med"},{"key":"2025121220300172000_8.2.e019325.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2014.10.004"},{"key":"2025121220300172000_8.2.e019325.15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jare.2015.01.008","article-title":"Identification of rheumatoid arthritis biomarkers based on single nucleotide polymorphisms and haplotype blocks: a systematic review and meta-analysis","volume":"7","author":"Saad","year":"2016","journal-title":"J Adv Res"},{"key":"2025121220300172000_8.2.e019325.16","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/BOR.0000000000000253","article-title":"Is rheumatoid arthritis an autoimmune disease?","volume":"28","author":"Chemin","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"2025121220300172000_8.2.e019325.17","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1514152112"},{"key":"2025121220300172000_8.2.e019325.18","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s00011-015-0882-1","article-title":"Association between FCGR3B copy number variations and susceptibility to autoimmune diseases: a meta-analysis","volume":"64","author":"Lee","year":"2015","journal-title":"Inflamm Res"},{"key":"2025121220300172000_8.2.e019325.19","doi-asserted-by":"publisher","DOI":"10.1186\/ar3013"},{"key":"2025121220300172000_8.2.e019325.20","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/nrrheum.2016.119","article-title":"Deregulation and therapeutic potential of microRNAs in arthritic diseases","volume":"12","author":"Vicente","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"2025121220300172000_8.2.e019325.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2016.09.003"},{"key":"2025121220300172000_8.2.e019325.22","doi-asserted-by":"crossref","unstructured":"Kruse Meyer M , Andersen M . Effect of IL-6R inhibition with tocilizumab on the proteome of peripheral blood mononuclear cells from a rheumatoid arthritis patient. J Proteomics Bioinform 2015;8.doi:10.4172\/jpb.1000380","DOI":"10.4172\/jpb.1000380"},{"key":"2025121220300172000_8.2.e019325.23","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1021\/acs.jproteome.6b00598","article-title":"Proteome analysis of rheumatoid arthritis gut mucosa","volume":"16","author":"Bennike","year":"2017","journal-title":"J Proteome Res"},{"key":"2025121220300172000_8.2.e019325.24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0153140","article-title":"Independent candidate serum protein biomarkers of response to adalimumab and to infliximab in rheumatoid arthritis: an exploratory study","volume":"11","author":"Ortea","year":"2016","journal-title":"PLoS One"},{"key":"2025121220300172000_8.2.e019325.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jprot.2012.09.011"},{"key":"2025121220300172000_8.2.e019325.26","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2016.1"},{"key":"2025121220300172000_8.2.e019325.27","doi-asserted-by":"publisher","DOI":"10.1002\/art.27584"},{"key":"2025121220300172000_8.2.e019325.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2010.05.007"},{"key":"2025121220300172000_8.2.e019325.29","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.104018"},{"key":"2025121220300172000_8.2.e019325.30","unstructured":"DANBIO. Dansk reumatologisk database. www.danbio-online.dk (accessed 4 Jul 2017)."},{"key":"2025121220300172000_8.2.e019325.31","unstructured":"Danish Regions. Bio- and Genome Bank Denmark. http:\/\/www.regioner.dk\/rbgben (accessed 4 Jul 2017)."},{"key":"2025121220300172000_8.2.e019325.32","doi-asserted-by":"crossref","unstructured":"Kringelbach TM , Glintborg B , Johansen J , et al . The nationwide Danish Rheumatologic Biobank \u2013 paving the road to personalized treatment of patients with inflammatory rheumatic diseases. Eur Leag Against Rheum 2016.","DOI":"10.1136\/annrheumdis-2016-eular.2666"},{"key":"2025121220300172000_8.2.e019325.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2014.07.014"},{"key":"2025121220300172000_8.2.e019325.34","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2147\/CLEP.S99490","article-title":"The Danish nationwide clinical register for patients with rheumatoid arthritis: DANBIO","volume":"8","author":"Ibfelt","year":"2016","journal-title":"Clin Epidemiol"},{"key":"2025121220300172000_8.2.e019325.35","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210742"},{"key":"2025121220300172000_8.2.e019325.36","doi-asserted-by":"crossref","unstructured":"Glintborg B , Kringelbach T , Bolstad N , et al . Drug concentrations and anti-drug antibodies during treatment with biosimilar infliximab (CT-P13) in routine care. Scand J Rheumatol 2018:1\u20134.doi:10.1080\/03009742.2017.1376110","DOI":"10.1080\/03009742.2017.1376110"},{"key":"2025121220300172000_8.2.e019325.37","first-page":"S141","article-title":"Monitoring patients with rheumatoid arthritis in routine care: experiences from a treat-to-target strategy using the DANBIO registry","volume":"32","author":"Hetland","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"2025121220300172000_8.2.e019325.38","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev341"},{"key":"2025121220300172000_8.2.e019325.39","doi-asserted-by":"publisher","DOI":"10.1207\/S15327752JPA8103_01"},{"key":"2025121220300172000_8.2.e019325.40","first-page":"270","article-title":"Non-medical switch from originator to biosimilar infliximab in patients with inflammatory arthritis \u2013 impact on s-infliximab and antidrug-antibodies. Results from the Danish Rheumatologic Biobank and the DANBIO Registry [abstract number 1997]","volume":"68","author":"Glintborg","year":"2016","journal-title":"\u00a0Arthritis Rheumatol"},{"key":"2025121220300172000_8.2.e019325.41","first-page":"270","article-title":"Clinical and genetic associations of radiographic sacroiliitis and its different patterns in psoriatic arthritis","volume":"35","author":"Haroon","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"2025121220300172000_8.2.e019325.42","unstructured":"DANBIO. National \u00e5rsrapport 2015, 2016."}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2017-019325","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T04:30:16Z","timestamp":1765600216000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2017-019325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":42,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,2,1]]},"published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.1136\/bmjopen-2017-019325"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2017-019325","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2]]}}}